Application of long-chain non-coding RNA MYLK-AS1 as biomarker in preparation of kit for diagnosis or prognosis of acute myelogenous leukemia

By using LncRNA-MYLK-AS1 as a biomarker, the shortcomings of existing technologies in the diagnosis and prognosis of AML are addressed, providing a precise diagnostic and prognostic assessment method, enhancing chemotherapy sensitivity, and making it suitable for clinical screening.

CN122256512APending Publication Date: 2026-06-23CHINESE PEOPLES LIBERATION ARMY KET FORCE CHARACTERISTIC MEDICAL CENT
0 Cites 0 Cited by

Patent Information

Application Number
CN202610639743.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-05-11
Publication Date
2026-06-23

AI Technical Summary

Technical Problem

Current diagnostic methods for acute myeloid leukemia (AML) rely on morphological examinations, which have low sensitivity and are prone to misdiagnosis and missed diagnosis. Prognostic stratification indicators cannot fully reflect the potential for disease progression, and there is an urgent need for novel and precise biomarkers.

Method used

Using LncRNA-MYLK-AS1 as a biomarker, we can determine the diagnosis and prognosis of AML by detecting its expression level in the peripheral blood of patients. We provide diagnostic and prognostic kits, including specific primers and qPCR amplification mixes, construct LncRNA-MYLK-AS1 knockdown cell lines and enhance sensitivity with chemotherapeutic drugs.

Benefits of technology

It enables early and accurate diagnosis and effective prognostic assessment of AML, is simple to operate and has high detection accuracy, laying the foundation for targeted therapy of AML and enhancing chemotherapy sensitivity.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses application of long-chain non-coding RNA (Ribonucleic Acid) MYLK-AS1 as a biomarker in preparation of a kit for diagnosis or prognosis of acute myelogenous leukemia. The invention aims to provide a marker for diagnosis and / or prognosis of acute myelogenous leukemia and a therapeutic target. The invention discloses application of LncRNA-MYLK-AS1 serving as a biomarker to preparation of a kit for diagnosis and / or prognosis of acute myelogenous leukemia. The gene of the LncRNA-MYLK-AS1 is shown as SEQ ID NO. 1. The invention further discloses application of the LncRNA-MYLK-AS1 to preparation of a kit for diagnosis and / or prognosis of acute myelogenous leukemia. As a clinical diagnosis and prognosis marker, the LncRNA-MYLK-AS1 provided by the invention has the advantages that the operation is simple, the detection is accurate, the LncRNA-MYLK-AS1 is suitable for clinical screening, more information is provided for diagnosis and prognosis of AML, and a foundation is also laid for targeted therapy of AML.
Need to check novelty before this filing date? Find Prior Art